Virtual Advocacy Summit Table of Contents

I. Welcome Letter from Dr. Monica Bertagnolli; Chair of the Association Board

a. Virtual Advocacy Summit Agenda

b. ASCO Association PAC

c. Join Us on Social Media - A Tip Sheet

II. ASCO Legislative Messages for Congress

a. Improving Diversity in Clinical Trials Face Sheet

i. CLINICAL TREATMENT Act (H.R. 913) Infographic Leave Behind

b. Step Therapy Face Sheet

i. Safe Step Act (H.R. 2279/S. 2546) Leave Behind

c. COVID-19 & Cancer Care Face Sheet

i. Leave Behind

d. Suggested Meeting Script

III. Speaker Biographies

a. Biography for Nicole Tisdale; Advocacy Blueprints

b. Biography for Nathan Gonzales; Inside Elections and Political Analyst

c. Biography for Representative Rosa DeLauro; Recipient of ASCO’s Congressional Champion for

Cancer Care Award

IV. ASCO Advocates

a. ASCO’s 2019 Grassroots Advocacy Champions

b. 2020 Virtual Advocacy Summit Attendee List

V. Technology Resources

a. Accessing the Virtual Congressional Meeting Scheduling Website

b. WebEx How-to: Dialing in to Virtual Events

September 03, 2020

Dear ASCO Advocates:

I would like to thank each of you for your unwavering advocacy even when facing the challenges of the ongoing pandemic. Your participation remains critical to advancing ASCO’s top priorities on Capitol Hill. We are excited that for our first ever Virtual Advocacy Summit, we have over 170 volunteers participating, from 17 ASCO Committees, and 27 State Affiliates representing 44 states, Puerto Rico and the District of Columbia. As practicing physicians, researchers and constituents, you are well equipped to influence the outcome of several key issues this year.

Congress continues to generate policies that impact our ability to care for patients and direct constituent contact is the most effective way to ensure they make the best-informed decisions possible. The Virtual Advocacy Summit gives you that opportunity by allowing you to develop new, or build on existing, relationships with your Members of Congress and their staff. We understand this is different and may feel difficult in a virtual setting, but rest assured that lawmakers and their staff are used to virtual meetings and very much want to hear from their constituents. As with an in-person Advocacy Summit, we have prepared programming to help you prepare for your virtual congressional meetings and your ongoing, year-round advocacy efforts. We have also transitioned the keynote speaker to a virtual event to provide you with an insightful analysis of the upcoming election.

As you prepare for your meetings, we encourage you to utilize these materials, also accessible through the Advocacy Summit webpage, which is a central hub for your Summit experience. It Includes tip sheets for mastering the virtual meeting and the accompanying technology, background on the topics on which we will advocate, a meeting script to guide your meeting group with messages, and information on our exciting line up of speakers over the next couple of weeks. We will discuss these issues in greater detail as part of the Virtual Advocacy Summit programming.

Congressional schedules are constantly shifting, and meeting schedules may not be finalized until closer to the Summit date. Your individual schedule will be available online beginning Friday, September 11th; instructions on how to access it are included in the Summit materials. Look for an email from ASCO staff with the web link and information on how and when to get in touch with your meeting groups. Please remember that these meetings are scheduled for you, and if you are unable to attend it is imperative you let ASCO staff know so they can let the other participants know or cancel the meeting if you are the only constituent attendee. For some of you who may be the only participant from your state, an ASCO staff person will join for your virtual meetings and we will let you know that as well.

I will leave you with one last exciting announcement. As you know, earlier this year, the American Society of Clinical Oncology (Society) launched the Association for Clinical Oncology (Association), a 501(c)(6) professional association that enables expanded advocacy activities and increases the impact of efforts directed towards policymakers in support of high-quality patient care. At that time, all members of the Society also became members of the Association – this type of dual membership is known as reciprocal membership. Our mission has never been more critical in a time of fast-moving science, healthcare reform, cost increases, and other pressures. I am pleased to share with you, our most engaged advocates, that in 2020 we have launched our Political Action Committee (PAC), the ASCO Association PAC, which will expand our advocacy activities and increase the impact of efforts directed toward policymakers in support of high-quality patient care. For more information regarding the PAC, we’ve included a one-page PAC infographic in these materials. If you have questions about the Advocacy Summit, please contact Katie Gifford at AdvocacySummit@asco.org or (571) 483-1601. I look forward towards the collective effort of making this first Virtual Advocacy Summit the most successful Summit to date! Sincerely,

Monica M. Bertagnolli, MD, FACS, FASCO Chair of the Board, Association for Clinical Oncology

Thursday, September 10, 2020

Tuesday, September 15, 2020

Wednesday, September 16, 2020

7:00 - 8:30 PM (EST): Virtual Hill Meeting Prep What to Know & What to Say (Live webinar, will be recorded)

Virtual Advocacy Summit Welcome Virtual Hill Meeting Walk-ThroughCongressional OutlookLegislative Messaging Q&A

7:00 – 8:00 PM (EST): Prepare for Success: Advocacy Tool and Tips (Live webinar, will be recorded)

Nicole Tisdale, Founder and Principal at Advocacy Blueprints & Former Hill StafferThe Importance of Advocacy What Really Influences Legislators Telling a Story vs. Sharing Stats We Met, Now What?

7:00 – 8:00 PM (EST): Virtual Office Hours with a Pro (Live webinar)

Nicole Tisdale, Founder and Principal at Advocacy Blueprints & Former Hill StafferNicole will be available for the hour to answer any questions you may have regarding her presentation or anything else advocacy related

8:00 – 10:00 AM (EST): Coffee with ASCO (Live webinar)

Have questions about what to expect and the legislative messaging? ASCO staff will be available to answer your questions

9:00 AM – 7:00 PM (EST): Virtual Congressional Meetings

Pre-scheduled virtual meetings with your Members of Congress & their staff Individual schedules will be provided

7:30 – 9:00 PM (EST): Keynote Speaker: Political Outlook & 2020 Elections (Live webinar)Presentation of ASCO’s Advocate of the Year Award

Carolyn Hendricks, MD, FASCO

2020 Election Insights

Nathan Gonzales, Inside Elections

Wednesday, September 9, 2020 V

irtual A

dvo

cacy Sum

mit: 2

02

0 A

gen

da

Tune in to hear from a veteran Washington DC insider who has covered elections for over a decade. Nathan will discuss the current state of play and what to expect in this fall's biggest races.

ASCO Government Relations Committee Leadership

5:00 - 5:30 PM (EST): Presentation of ASCO's Congressional Champion for Cancer Care Award to Representative Rosa DeLauro (CT-03) (Live webinar)

The Association for Clinical Oncology (ASCO) is the nation’s leading organization supporting high-quality cancer care, cancer-focused research, and the cancer care delivery team. The ASCO Association political action committee (PAC) helps us influence positive change on Capitol Hill for the cancer care community. The PAC provides us with a collective voice in the political arena by allowing us to support the campaigns of candidates who understand the importance of our work in oncology and how it impacts the patients we treat.

1

2

3

4

5

6

Eligible members make voluntary contributions

to the PAC.

All Association member contributions are pooled together. The PAC Advisory Council,

made up of a diverse group of our members, reviews and

approves candidates based on a strict list of guidelines

to ensure only champions for cancer research and

high-quality cancer care receive our support.

Guidelines for supporting candidates include:

a. Those who promote Associationadvocacy priorities

b. Candidatesrunningforfederalofficeand national party committees

c. Priority to members of CongressionalCommittees with jurisdiction overMedicare, appropriations, and healthprograms, and physician candidateswho support Association prioritiesOur PAC is

nonpartisan.

The elected candidates we support will make an impact on health care policy decisions that affect the future of cancer care and the important work we do on behalf of our patients.

Path of an ASCO Association PAC Contribution

Now is the time to make your voice heard. Help us create positive change for cancer care. Click here to join ASCO Association PAC today!

We educate legislators on the current realities of the cancer care delivery system and the need to provide high-quality, affordable cancer care to our patients.

The PAC supports lawmakers who prioritize policies important to the future of cancer care and our advocacy priorities.

Our PAC helps us engage with lawmakers from both sides of the aisle to ensure our members’ voices are heard in D.C.

ENGAGE EDUCATE SUPPORT

Contributions to ASCO Association PAC are not tax deductible for federal income tax purposes. Contributions are used for political purposes and are strictly voluntary. You may refuse to contribute without reprisal. The guidelines are merely suggestions. You are free to contribute more or less than the guidelines suggest and the association will not favor or disadvantage you by reason of the amount contributed or the decision not to contribute. Federal law requires ASCO Association PAC to use our best efforts to collect and report the name, mailing address, occupation and the name of the employer of individuals whose contributions exceed $200 in a calendar year. You must be a U.S. citizen or permanent resident (green card holder) in order to contribute.

Social Media Tips

Help Spread the Word

› Use #ASCOAdvocacySummit in tweets during the Summit!

› Search for the #ASCOAdvocacySummit to see what others are saying. Retweet or share other users’ posts to help amplify the message.

› Reply publicly to other users’ tweets with your own thoughts.

› Tag @ASCO and Members of Congress in your tweet.

› Tweet directly at your lawmaker for greater impact.

Tips & Tricks

› ASCO is a non-profit, non-partisan organization. Please consider this when presenting your message throughout the day.

› When writing your post or tweet, be clear and concise, and state your motivations for joining the discussion. Keep these goals top-of-mind to make sure your messaging stays consistent throughout the day.

› Make it personal by sharing your connection to the legislation.

› Give credit when credit is due through retweets and shares whether they be from a Member of Congress, colleague, or organization, and always link to your sources.

› Social media is especially important this year because of our event is virtual, consider content unique to this time such as mask selfies.

Tweet During #ASCOAdvocacySummit Here are examples of a well-constructed tweet. Feel free to use!

› Meeting virtually with @ASCO volunteers to urge Congress to improve the quality of research and reduce disparities by passing the CLINICAL TREATMENT Act #ClinicalTrialAccess #ASCOAdvocacySummit

› Thank you @TagYourMemberHere for taking time to discuss how COVID-19 has impacted cancer care and steps we can take to ensure our patients have access to telemedicine #ASCOAdvocacySummit

› Great meeting with @TagYourMemberHere staff about how step therapy is creating barriers to timely access to cancer care for patients. #ASCOAdvocacySummit

› Wrapping up my last virtual #ASCOAdvocacySummit meeting advocating to protect

cancer care. {Consider including photo from your location}

› Join us by telling your member of #Congress to support cancer policy priorities at

asco.org/actnetwork. #ASCOAdvocacySummit

Improve Diversity in Clinical Trials House: Co-sponsor H.R. 913, the CLINICAL TREATMENT Act Senate: Once introduced, support companion legislation

• The current crisis has only exacerbated existing disparities in health care, including lack of minority representation in clinical research.

• Medicaid is the only major payer not required by federal law to provide coverage of the routine care costs for patients participating in a clinical trial.

• Medicaid enrollment is highly sensitive to changes in unemployment rates, it is the most important source of public coverage for those losing employer sponsored insurance, with nearly half projected to be eligible and/or enroll.

• Clinical trials are often the best clinical option for patients with cancer and benefit them in ways that go beyond the value of the research data generated within the trial.

• Increasing overall enrollment and diversity in clinical trials improves the validity of clinical research data and quality of new treatments.

Protect Appropriate Patient Care House: Co-sponsor H.R. 2279, the Safe Step Act Senate: Co-sponsor S. 2546, the Safe Step Act

• Step therapy is generally not appropriate in cancer care because it can severely delay access to the best treatment available, which may result in disease progression and preventable complications.

• Step therapy can cause other problems in cancer care, including a reduction in health care quality, a burden on

patients and their providers and an increase in health care costs.

• Patients should be protected from harmful step therapy protocols with a clear exceptions process for specific instances where a provider deems it medically necessary.

• Many patients are changing insurance now because of changes in employment status, this bill would protect them from having to repeat step therapy protocols because of a change in insurance.

COVID-19 & Cancer

House & Senate: Discuss impact of COVID-19 on your practice and/or research. If your practice has benefited from recent federal aid funds, offer thanks. Ask for Congress to come to agreement on needed changes for telehealth and research funding. Permanently lift the geographic and site restrictions on telehealth technologies so all Medicare beneficiaries have access to telehealth services, including from home, regardless of where they live.

• Telemedicine services provide health professionals with another valuable way to continue to treat their patients.

• Continuation of current payments and flexibilities beyond the public health emergency would allow for patients

across the country to receive the care they need with little interruption.

• By eliminating travel, telehealth can save patients time and money, and more immediately, it allows

immunocompromised patients to avoid exposing themselves to potential health risks.

Increase baseline funding and provide emergency funding for the National Institutes of Health (NIH) and the National Cancer Institute (NCI) to mitigate the disruptions to clinical trials and medical research and build on previous investments.

• Many labs across the country have had to suspend or adjust their research as a result of the COVID-19 pandemic.

• Individuals, especially young investigators and support staff are at risk of losing their employment as well as their

current research progress, and the longer our clinical trials network is stagnant patients will miss out on potentially

life-saving treatments.

• Robust funding for the NIH is critical to get our nation’s biomedical research enterprise and clinical trials network fully

running once safe.

• NCI's funding has continued to lag in proportion to the NIH, and with so many promising cancer treatments in the

research pipeline, it is critical that NCI's baseline funding receives proportional increases to that of NIH.

ADVOCACY SUMMIT

SEPTEMBER 16, 2020 VIRTUAL

Agenda Item under Discussion: The CLINICAL TREATMENT Act (H.R. 913)

Background:

ASCO has urged policymakers to ensure access to life-saving screening, treatment, and prevention services for low-income Americans with cancer. Guaranteed access to clinical trials is an important part of high-quality cancer care and should be available to every patient with cancer, regardless of financial circumstances, including the coverage of routine patient care costs when participating in clinical trials. Routine care includes items and services that a payer would cover for a patient not enrolled in a clinical trial, such as office visits, radiology exams, and laboratory tests.

Last year, ASCO helped secure House reintroduction of H.R. 913, the CLINICAL TREATMENT Act, led by Representatives Ben Ray Luján (D-NM) and Gus Bilirakis (R-FL). While ASCO and members of the broader medical community have been working to raise congressional awareness of this issue and gain co-sponsors for the bill, the Advocacy Summit is a great opportunity for Members to hear from constituents to support the bill. Medicaid is the only major payer that does not currently provide this coverage. Medicare has provided this coverage for beneficiaries’ participation in trials since a 2000 Medicare National Coverage Determination. The Affordable Care Act included a provision that requires private plans to cover routine patient care costs for trials participation. Only 15 states and D.C. guarantee coverage of routine care costs associated with trials participation for Medicaid beneficiaries; most states do not. ASCO has worked with the stakeholder community to gather support for the CLINICAL TREATMENT Act, and after the reintroduction of the bill, ASCO led a community endorsement letter to the bill’s sponsors with 106 healthcare groups signed on. Over the past year, the legislation has gained more congressional support, with 36 bipartisan co-sponsors in the House. ASCO is working with the bill’s leads on a few potential paths forward for the bill. ASCO led a community letter to House and Senate leadership asking for it to be considered as part of any future COVID-19 relief legislation, pointing to how the pandemic has exacerbated existing disparities in access to care for vulnerable populations. Additionally, ASCO advocated for the concepts of H.R. 913 included in a 21st Century Cures 2.0 concept paper released by Representatives Diana DeGette (D-CO) and Fred Upton (R-MI). The goal of the concept paper is to outline a potential legislative package focused on access to care, and the CLINICAL TREATMENT Act would be a good fit. Finally, ASCO continues to work with House Energy and Commerce Committee leadership to ensure they understand the importance of the bill. Committee leadership in the House and Senate have indicated that the bill could be included in a must-pass Medicaid extenders package later this fall, so increasing support for the bill at the Advocacy Summit is critical. ASCO has been working closely with interested offices in the Senate and hope to have a companion bill introduced soon. In the meantime, we would like to build as much support as possible so the bill will have momentum when introduced. Messages for Congress: House: Cosponsor the CLINICAL TREATMENT Act (H.R. 913) If already cosponsoring: Thank you! Senate: Once introduced, support companion legislation.

ADVOCACY SUMMIT SEPTEMBER 16, 2020 VIRTUAL

Agenda Item under Discussion:

The Safe Step Act (H.R. 2279/S. 2546)

Background:

Step therapy is a utilization management tool that requires patients to try and fail medications chosen by a payer before the payer will cover a medication originally prescribed by the patient’s health care provider. During this process, providers must demonstrate that the payer-preferred drug has been unsuccessful in treating a patient’s condition before the patient can access the provider-recommended drug. These policies are also referred to as “fail first” procedures.

Step therapy policies are inappropriate for use in oncology due to the individualized nature of modern cancer treatments and the general lack of interchangeable clinical options. For patients with cancer, step therapy can severely delay access to the best treatments available for their condition. While patients go through the step therapy process, they can experience disease progression and irreversible damage to their overall health. Other issues step therapy can cause in cancer care include:

• Potentially irreversible disease progression and other significant patient health risks due receiving an inferior treatment

• Deterioration of the provider-patient relationship

• An increase in health care costs caused by delays and disease progression

• Administrative burden on patients and their providers

The Safe Step Act (H.R. 2279), is being led by Representatives Raul Ruiz, MD (D-CA) and Brad Wenstrup, MD (R-OH) in the House and its Senate counterpart, S. 2546, was introduced by Senators Lisa Murkowski (R-AK), Doug Jones (D-AL), Bill Cassidy (R-LA), Maggie Hassan (D-NH), Cindy Hyde-Smith (R-MS), and Jacky Rosen (D-NV). The bills aim to mitigate the barriers caused by step therapy protocols in ERISA-governed health plans by requiring exceptions when:

1. Treatment is contraindicated 2. Treatment is expected to be ineffective 3. Treatment likely to cause adverse reaction 4. Treatment expected to decrease the patient’s ability to perform daily activities 5. Patient is stable based on the prescription drugs already selected

Due to the current state of the economy, patients who have a change in insurance coverage because of a loss or change in employment may be subject to endure new or additional step therapy protocols, making the passage of these protections even more important right now. ASCO has joined community letters urging inclusion of this bill in future COVID-19 relief legislation.

Currently, both the House and Senate bills enjoy broad bipartisan support and has 146 and 16 cosponsors respectively. Congressional awareness of the harm step therapy can have on patients has increased, and there is an appetite to address these harmful utilization management policies.

Message to Congress: House: Cosponsor the Safe Step Act (H.R. 2279)

If already a cosponsor: Thank you! Senate: Cosponsor the Safe Step Act (S. 2546) If already a cosponsor: Thank you!

Step therapy is a utilization management tool that requires patients to try and fail medications chosen by a

payer, before the payer will cover the medication originally prescribed by their health care provider. This

policy approach is also often referred to as “fail first.” Step therapy policies are generally inappropriate for use

in oncology due to the individualized nature of modern cancer treatment and the general lack of

interchangeable clinical options.

Step therapy can lead to disease progression and can create irreversible damage to a patient’s health. One

study found that patients with breast cancer who experienced a delay of three months or more had a 12

percent lower 5-year survival rate than patients with shorter or no delays.

Step therapy undermines the doctor-patient relationship. Oncologists are educated on the complexities of

cancer care and are trained to assess, diagnose, and treat patients with cancer. Step therapy policies threaten

the doctor-patient relationship by requiring medication that is not what the doctor concludes is in the best

interest of the patient.

The Safe Step Act (H.R. 2279/S. 2546), led by Reps. Raul Ruiz, MD (D-CA) and Brad Wenstrup, MD (R-OH) in the House and Senators Lisa Murkowski (R-AK), Doug Jones (D-AL), Bill Cassidy (R-LA), Maggie Hassan (D-NH), Cindy Hyde-Smith (R-MS), and Jacky Rosen (D-NV) in the Senate, puts important patient safeguards from step therapy protocols in place for ERISA-governed health plans by requiring exceptions when the treatment is contraindicated, expected to be ineffective, likely to cause adverse reaction, or the patient is stable on treatment already selected.

Protect Appropriate Patient Care

Co-sponsor H.R. 2279/S. 2546, the Safe Step Act

“Stephen’s” Experience with Step Therapy Stephen was being treated for chronic myelogenous leukemia (CML), a cancer that affects a person’s blood cells and bone

marrow. When he began to have severe side effects from the treatment, his physician switched him to an alternative medication, and he was doing very well. When Stephen switched insurance plans, his new insurer refused to pay for the

medication he was already on, stating that it was not on the plan’s “first tier” for that category of medication. The insurer wanted him, according to their policy, to "fail" on another medication before approving the medication he was taking—and

which had been effective in treating his cancer. Stephen reluctantly agreed because he was unable to pay for his current medication without insurace, but severe side effects forced him to stop the required “fail first” treatment. During the time

that he was not taking medication, Stephen’s disease progressed severely and he eventually died.

“Ellen’s” Experience with Step Therapy A 52-year old mother of 3, Ellen was about to undergo chemotherapy for colon cancer. She hoped for a cure, but was very anxious about the side effects, especially nausea, since she experienced severe nausea with her pregnancies. Because of Ellen’s history, her physician prescribed a potent nausea medication (Emend) to avoid this complication. Ellen’s insurance

company refused to cover the recommended medication--even when she progressed to terrible nausea and vomiting on the plan’s approved, but less effective, medication. Because Ellen could not afford the medication without insurance coverage, she endured an avoidable complication for her first cycle of chemotherapy. The health plan eventually permitted Emend in

subsequent treatments, but their “fail first” policy came at the expense of Ellen realizing her fears, demoralizing her efforts to stay healthy, and creating unnecessary anxiety that medications for nausea would not work for her.

Step-Therapy: A Barrier to Patient

Access to Cancer Care

ADVOCACY SUMMIT

SEPTEMBER 16, 2020 VIRTUAL

Agenda Item under Discussion: COVID-19 Impact on Cancer Care and Research

Background: The COVID-19 pandemic has had a severe impact on communities across the country and Congress has their attention on mitigating the effects of the pandemic across all sectors of society. Cancer care providers and researchers have been impacted by the public health crisis in many ways. Providers have dealt with personal protective equipment (PPE) shortages, patients missing screenings and visits causing avoidable disease progression, a reduction in staff and office space due to social distancing needs, difficulty ensuring practices have the financial support needed to continue providing quality cancer care, shifting work from face to face to telehealth, and much more. Researchers have dealt with lab closures as space has been redirected to COVID research, or in situations where research cannot continue safely. This has led to job insecurity, especially for younger investigators and support staff, as well as a costly loss in research progress. Additionally, clinical trials have halted or slowed in many areas and the longer trials are shut down, the longer patients are denied possible life-saving treatments. It will require financial investment to get the nation’s biomedical research enterprise fully up and running again. Congress is working on the next COVID-19 relief package and is eager to hear from constituents about how the pandemic has affected them and their work to determine what might be needed in the next package. With input from ASCO members and Committees, ASCO has identified two areas where Congressional support is necessary for cancer care providers, researchers, and their patients. The use of telehealth has sharply increased during COVID-19, and it has greatly benefitted patients. ASCO’s first COVID request is for Congress to permanently lift the geographic and originating site restrictions on telehealth technology in Medicare. Congress must also ensure all payers will continue to cover and reimburse for audio-only visits and reimburse telehealth visits at the same rate as in-person visits so that all patients have access to these services regardless of their location, and Congress must continue working with the Administration to guarantee the use of telehealth can continue uninterrupted even after the public health emergency ends. ASCO has joined community letters to Congress, the Administration and payers advocating for these permanent changes. Additionally, ASCO has joined the biomedical research community in requesting Congress include emergency funding for the NIH and NCI in the next relief bill to restart research and help mitigate the financial disruptions caused by COVID-19. We ask that the next package include $15.5 billion for the NIH in emergency funding to mitigate disruptions to research and clinical trials. There is bipartisan support for this funding in Congress as well. A letter circulated in both chambers was sent to House and Senate leadership requesting $15.5 billion in emergency funding for the NIH. While ASCO has selected these two actionable issues to highlight, there are many more COVID-19 issues oncologists and researchers are grappling with. Advocacy Summit participants are encouraged to briefly elaborate on any other issues they are facing such as those outlined earlier in this document. Message to Congress: House & Senate: Telehealth: Extend the current coverage, reimbursement, and flexibilities from all payers for telehealth services. In Medicare, eliminate the geographic and originating site restrictions and continue coverage for audio-only services. Research: Provide NIH with $15.5 billion in emergency funding to mitigate disruptions to biomedical research and clinical trials caused by COVID-19. Signed the Dear Colleague Letter Supporting this Funding: Thank you!

As with nearly every facet of life, cancer care and research have been significantly impacted by the

novel coronavirus pandemic. Oncologists and their patients have dealt with personal protective

equipment (PPE) shortages and patients have missed screenings causing avoidable disease

progression. Many practices are struggling to ensure they have the financial support needed to

continue providing quality cancer care.

ASCO has worked to provide support to our members throughout this public health emergency in

the form of best practice reccomendations, opportunities to purchase PPE, and open dialogue

about what is needed to support immediate needs and what lessons learned can improve the

cancer care and research infastructure moving forward.

Researchers have dealt with lab closures as space has been redirected to COVID research or

because research cannot continue safely. This has led to job insecurity, especially for younger

investigators and support staff, as well as a costly loss in research progress. Additionally, clinical

trials have halted or slowed in many areas and the longer trials are shut down, the longer patients

are denied possible life-saving treatments. It will require financial investment from Congress to get

the nation’s biomedical research enterprise up and running again.

Congress can further provide support for cancer patients in the form of emergency funding to mitigate disruptions in research. $15.5 billion dollars is needed for the National Institutes of Health (NIH) in the form of emergency funding. This emergency funding should not negate needed boosts to the underlying budgets at both NIH and the National Cancer Institute (NCI). The use of telehealth has sharply increased during COVID-19, and in some ways has greatly benefitted patients with cancer. Its availability should not be restricted after the public health emergency ends. Congress should permanently lift the geographic and originating site restrictions on telehealth technology in Medicare. Congress must also work to ensure all payers will continue to cover and reimburse for audio-only visits and reimburse telehealth visits at the same rate as in-person visits so that all patients have access to these services regardless of their location.

Protect Appropriate Patient Care

COVID-19 and Cancer Expand Telehealth and Support Research

Expand Telehealth: Extend flexibilities from all payers for telehealth services. In Medicare, eliminate the geographic and originating site restrictions and continue coverage for audio-only services. Support Research: Provide NIH with $15.5 billion in emergency funding to mitigate disruptions to biomedical research and clinical trials caused by COVID-19.

Step-Therapy: A Barrier to Patient

Access to Cancer Care

Advocacy Summit Suggested Meeting Script Virtual meetings present unique challenges because the ability to read body language cues or make eye

contact is typically not available. This is intended as a guide to help your meeting group prepare and mitigate some of these challenges. We encourage you to make these meetings your own and use your words and

personal stories whenever possible. Reminders:

o We will connect you with your group via email before September 16th so that you can identify a group leader for each meeting. If you are the only attendee from your state, you will likely be partnered with an ASCO staff person.

o In your group, a constituent should be the leader for each meeting. o Agree in advance the order in which you will speak & you can reference the script for your turn. o Depending on the size of your group, you may wish to break this up or condense this to reflect the

number of participants. o Please avoid talking over each other as much as possible. o If you are not speaking, please mute yourself to avoid distracting background noise. o Be sure to pause for questions or comments periodically. o Prior to beginning, check your online schedule to see if the lawmaker already supports our issues. o After the call, please provide feedback on your lawmaker’s stance on our issues in the notes section of

your Congressional Meeting Schedule (located here or go to http://clients.primeadvocacy.com/attendee/login)

Introductions:

Group Leader:

Hi [Lawmaker/staffer name], I am [name] from [practice/institution] and I live in [town/state]. Thank you for

taking the time to speak with us today. I’ll get back to why we asked for this meeting, but I’m going to quickly

turn it over to my colleagues to introduce themselves.

[Each group member introduces themselves: Name, practice/institution, town/state.]

Purpose of Meeting:

Group Leader:

We are here on behalf of the Association for Clinical Oncology, or ASCO. ASCO represents nearly 45,000 cancer

care providers and researchers. We would much rather be visiting with you in person, but we really appreciate

your time today. We have a few topics we’d like to discuss with you.

Before we get into our messages, I want to note that the materials for our discussion were sent to you via a

web link along with the conference line.

I’m now going to turn to my colleagues, who will each tell you a little bit more about why we are here.

ASK #1: CLINICAL TREATMENT Act

Speaker 1:

Thanks again for taking the time to speak with us. The first issue we would like to discuss with you is the

CLINICAL TREATMENT Act (H.R. 913).

• This bipartisan bill was introduced by Representatives Ben Ray Luján (D-NM) and Gus Bilirakis (R-FL) and would require Medicaid to cover the routine care costs for patients with life threatening conditions participating in an approved clinical trial for enrollees.

• Routine costs include non-experimental costs, like routine laboratory tests, screenings and physician visits. The trial sponsor would still cover the investigational item like the drug or treatment.

• Medicaid is the only major payer that is not required to cover these costs on clinical trials – both Medicare and private payers are federally required to do so.

• If a patient is treated off of a clinical trial, or by standard of care, Medicaid is required to cover these routine care costs. However, often with complex, life threatening conditions the best or only viable treatment option is participating in a clinical trial – by not covering routine costs, Medicaid enrollees are effectively excluded from these trials.

• Another critical reason to pass this bill is that Medicaid enrollees are vastly underrepresented in clinical trials. Medicaid disproportionately covers ethnic and racial minorities, women, children, and rural populations. In order for our treatments to have the best clinical outcomes once approved, we need to include all population cohorts in trials. We’re seeing the importance of this right now with the ongoing trials for a COVID-19 vaccine.

[May be a good break point to move to another speaker if your group is large]

• We have had some success at the state level, with 15 states plus D.C. providing coverage for these routine care costs on clinical trials for Medicaid enrollees, but state by state progress is slow and sporadic.

• [Lawmaker’s State] [does/does not] provide coverage to its Medicaid enrollees. [refer to map in materials]

• Medicaid covers one-fifth of the US population, and even with the state success we’ve had, nearly 40 million Americans are still without this coverage on trials.

• COVID-19 has highlighted existing disparities in our healthcare system. And many states have seen a rise in Medicaid enrollment as the pandemic has continued, making this legislation all the more critical.

• We understand that a concern for Congress is the cost of a bill like this – many of the states that provide this coverage released fiscal notes indicating no or very minimal cost to their Medicaid program. If you would be interested in a summary of those studies, I’d be happy to have a copy emailed to you.

• Additionally, since Medicaid already covers routine care costs for patients being treated on standard of care, one can reasonably assume extending the exact same coverage to patients being treated on clinical trials would not cost more – it would only expand that patient’s treatment options.

• ASCO has been working with the bill leads as well as Energy and Commerce and Finance Committee leadership on both sides of the aisle, and there is agreement that this is a commonsense bill.

• The bill has over 100 community endorsements, and ASCO led a community support letter to House and Senate leadership urging inclusion of this bill in upcoming COVID-19 relief legislation.

• We are asking you to please cosponsor the CLINICAL TREATMENT Act.

• IMPORTANT: [If Member is already a cosponsor of this bill thank them for that. This is noted on your online schedule]

• We’ve gone over a lot, but before we pause for questions, I want to ask my colleagues if they have any more to share on this important bill. [Pause to allow other ASCO participants to add comments or tell a personal story as to why this bill is important to them]

Group Leader: Before we move to the next issue, do you have any questions? I’m now going to ask my colleague to talk about our next Ask.

ASK #2: Safe Step Act

Speaker 3:

The next issue we would like to discuss is the use of step therapy or fail first in healthcare. Specifically, we’re

hoping you will support the Safe Step Act, (H.R. 2279/S. 2546).

• Step therapy, which is also often also called “step protocol” or “fail first,” is a utilization management tool used by many healthcare payers in hopes of controlling costs.

• Essentially, when a payer uses step therapy, they are requiring a patient to fail a payer-preferred treatment or medication before they will agree to cover the physician prescribed treatment.

• These payer-preferred treatments and medications are often less costly at first blush, but the consequences of step therapy to the patient and healthcare system can be great overall.

• If a patient’s access to the correct treatment is delayed because they must fail another treatment first, their condition could deteriorate – which can end up costing the healthcare system more and cause avoidable harm to the patient.

• In addition to disease progression and harm to the patient, delaying the appropriate care can also reduce the overall quality of healthcare provided. It is also detrimental to the patient/provider relationship.

• Overall, we believe that step therapy is inappropriate for cancer care.

• However, we recognize that it is a popular tool for payers, so we are advocating for passage of the Safe Step Act, which would at least establish exceptions to step therapy protocols in five specific instances:

o If the treatment is contraindicated or if a specific drug or treatment should not be used because it may be harmful to the patient,

o If the payer-preferred treatment is expected to be ineffective, o If the treatment is likely to cause an adverse reaction, and o If the treatment is expected to decrease a patient’s ability to perform daily activities.

• The Safe Step Act would implement a clear, easy to follow process for providers to access a step therapy exception whenever necessary.

• It is important to note that this bill would only apply to ERISA, or private, federally regulated insurance plans.

• The bill enjoys bipartisan support in the House and Senate, with 146 and 16 cosponsors respectively. It has a lot of support in the medical community as well.

[May be a good break point to move to another speaker if your group is large]

• COVID-19 has exacerbated the need for this bill.

• Immunocompromised patients, like cancer patients, should not be traveling to hospitals or medical institutions more than necessary right now – and a patient that is required to use step therapy or “fail first,” will likely require increased visits to their providers, and the delay in care could result in disease progression and further increase the number of doctor or hospital visits – each time risking exposure to COVID-19.

• This bill was introduced in a bipartisan way in both chambers – by Congressman Ami Bera of California and Congressman Brad Wenstrup of Ohio and Senators Lisa Murkowski (R-AK), Doug Jones (D-AL), Bill Cassidy (R-LA), Maggie Hassan (D-NH), Cindy Hyde-Smith (R-MS), and Jacky Rosen (D-NV).

• We hope you’ll consider cosponsoring the Safe Step Act.

• IMPORTANT: [If Member/Senator is already a cosponsor of this bill thank them for that. This is noted on your online schedule]

• I’d like to ask my colleagues if they have anything to add.

[Pause to allow other ASCO participants to add comments or tell a personal story as to why this bill is important to them]

Group Leader: Before we move to the next issue, do you have any questions? I’m now going to ask my colleague to talk about our next Ask.

ASK #3: COVID-19 and Cancer Care

Speaker 4:

Our third topic is to discuss with you is how COVID-19 has affected our practices, patients, and research and

what actions we believe it is critical Congress take to further mitigate the disruptions this pandemic has

caused.

• The COVID-19 pandemic has had a severe impact on all communities and sectors across the country.

• While there is a lot to be addressed in relation to COVID-19, we believe Congress needs to act on two main issues in the next COVID-19 relief package to shore up our healthcare system.

• First, we must restart cancer research & clinical trials to ensure that we do not lose any progress made over the last few years.

• Obviously, COVID-19 has upended our entire society, and this includes disrupting critical research funded by the National Institutes of Health (NIH) and the National Cancer Institute (NCI).

• Many labs across the country have had to suspend or adjust their research as a result of the COVID-19 pandemic.

• With these disruptions, many individuals, especially young investigators and support staff, are at risk of losing their employment as well as their current research progress.

• And the longer our clinical trials network is stagnant patients will miss out on potentially life-saving treatments.

• The impact of this pandemic on the entire biomedical research ecosystem, including cancer, is severe and relief is needed to ensure that labs and researchers can restart their operations.

• We are grateful that both the most recent House-passed and Senate-released COVID-19 relief bills included emergency funding for the NIH for medical research.

• We’re asking you to support $15.5 billion in emergency funding for the NIH in the next COVID-19 relief package.

• IMPORTANT: [If Member/Senator signed on to the Dear Colleague Letter supporting this level of emergency funding thank them for that. This is noted on your online schedule]

[May be a good break point to move to another speaker if your group is large]

• The other COVID-19 related topic we’d like to discuss is telehealth.

• There has been a dramatic increase in the use of telehealth services during the pandemic – and both patients and providers have benefitted from this.

• A report conducted by HHS found that in Medicare, telehealth services made up of less than 1% of visits in February, and by April were making up 43.5% of visits.

• We ask Congress to do whatever possible to continue telehealth payments and regulatory flexibilities.

• Telemedicine services provide health professionals with another valuable way to continue to treat their patients. Continuation of current payments and flexibilities beyond the public health emergency would allow for patients across the country to receive the care they need with little interruption.

• By eliminating travel, telehealth can save patients time and money, and more immediately, it allows immunocompromised patients to avoid exposing themselves to potential health risks.

• Any COVID-19 relief packages should permanently lift the geographic and site restrictions on telehealth technology in Medicare.

• Additionally, all payers must continue to cover and reimburse for audio-only visits and reimburse telehealth visits at the same rate as in-person visits to ensure all patients have access to these services regardless of their location.

• We urge Congress and the Administration to work together to ensure patients and providers can continue to rely on telehealth as appropriate, even after the current public health emergency.

• While we think these two areas should be addressed in the next COVID-19 package, we want to take a few minutes as constituents to tell you how COVID-19 has affected each of us and our research and patients.

[Pause to allow other ASCO participants to add comments or tell a personal story as to why this issue is important to them]

Closing the Meeting:

Group Leader: Thank you so much for taking the time to speak with us today. On behalf of all of us I want to offer us and ASCO as a resource for your office on cancer care or healthcare issues. Is there any information we can provide you as follow-up to what we’ve discussed today? Thanks again.

Nicole Tisdale, Founder and Principal, Advocacy Blueprints

Hear from Nicole:

Thursday, September 10, 7:00 p.m. (Eastern) – Prepare for Success: Advocacy Tools and Tips – Live,

recorded

Tuesday, September 15, 7:00 p.m. (Eastern) – Virtual Office Hours with a Pro – Live

Nicole Tisdale is the founder and principal of Advocacy

Blueprints. In this role, she works with individuals and

organizations who are eager to accelerate policy issues,

increase advocacy efforts, and create changes in their

organizations and communities.

Before founding Advocacy Blueprints, Nicole worked for the

United States Congress for more than a decade. She served

as the primary national security advisor, in the role of

Director and Counsel to the U.S. House of Representatives Committee on Homeland Security, for

Intelligence & Counterterrorism. She is known as an expert on a wide variety of policy issues and is a

well-respected collaborator known for her winning record of developing and executing bipartisan

legislative agendas. She managed and assisted with more than 100 congressional hearings, selecting

and questioning 350+ witnesses. She also helped to secure passage of 354 bills through the House of

Representatives, of which 80 went on to become law.

Nicole is also a best-selling author and accomplished keynote speaker. Her book, Right To Petition: A

Practical Guide to Creating Change in Government with Political Advocacy Tools, was released in

April 2019 and was widely praised. As a speaker, she works to drive the biggest possible impact with

each of her audiences, combining engaging stories, gorgeous visuals, and practical techniques that

push audiences to jump-start their creative energy and solve challenges in fresh, innovative ways.

Nathan Gonzales, Editor and Publisher of Inside Elections with Nathan L.

Gonzales, CNN Political Analyst and an Elections Analyst for Roll Call Newspaper

Hear from Nathan:

Wednesday, September 16 at 7:30pm EST - Live

Nathan Gonzales is the editor and publisher of Inside

Elections with Nathan L. Gonzales, which provides

non-partisan analysis of campaigns for Senate,

House, governor and president. He was an editor,

analyst, and writer for The Rothenberg Political

Report for more than 13 years before taking over the

company in 2015. He can regularly be seen on CNN

discussing the latest in politics, and the New York

Times, the Washington Post, the Wall Street Journal,

and USA Today have all sought him out for his expertise. On Election Night 2016, Nathan was an

on-air analyst for Newshour on PBS after working as an off-air consultant for ABC News on their

Election Night Decision Desk for 14 years.

In addition to publishing Inside Elections, Gonzales is also an elections analyst for Roll Call

newspaper. Before The Rothenberg Political Report, he worked for CNN.com and as associate

producer for CNN’s Capital Gang.

Gonzales has appeared on NBC’s Meet the Press and NBC Nightly News, C-SPAN’s Washington

Journal, and Fox News Channel. His work has also appeared on FiveThirtyEight,

WashingtonPost.com and NBCLatino.com, and in Campaigns & Elections magazine.

Gonzales grew up in Oregon, earned his Master of Arts from The George Washington

University’s Graduate School of Political Management (Washington, DC) and his Bachelor of

Arts from Vanguard University (Costa Mesa, California). He first came to Washington, DC, as an

intern in the White House Press Office and now lives in the city with his wife and four children.

Representative Rosa DeLauro (D-CT-3); Recipient of ASCO’s 2020 Congressional

Champion for Cancer Care Award

Hear from Representative DeLauro:

Wednesday, September 9 at 5:00pm EST – Live

Congresswoman Rosa DeLauro represents Connecticut’s Third

Congressional District. Representative DeLauro serves in the

Democratic leadership as Co-Chair of the Democratic Steering and

Policy Committee, and she is the Chair of the Labor, Health and

Human Services, and Education Appropriations Subcommittee,

where she oversees our nation’s investments in education, health,

and employment. The Congresswoman also serves on the

subcommittee responsible for the U.S. Department of Agriculture

and the U.S. Food and Drug Administration, where she oversees

food and drug safety.

Congresswoman DeLauro strongly believes in the power of biomedical research and she is

working to increase funding so that we can make lifesaving breakthroughs in science and

medicine. She has continuously supported cancer researchers, providers and patients through

her tireless work on the House Appropriations Committee. As the Chair dealing with

appropriations for Labor, Health, Human Services, and Education (LHHS), she has been a

stalwart advocate for increasing funding for the National Institutes of Health (NIH) and the

National Cancer Institute (NCI). In fact, throughout her tenure as Ranking Member and now

Chairwoman of the LHHS Appropriations Subcommittee, NIH has received an increase of $11.6

billion over the last five years. Last year, the NIH received an increase of $2.6 billion and the NCI

an increase of $300 million. As a cancer survivor herself, she has played an instrumental role

ensuring successful implementation of the Cancer Moonshot Initiative at NCI.

Through her position on the Appropriations Subcommittee on Agriculture, the Food and Drug

Administration, and Related Agencies, Congresswoman DeLauro has worked to lower tobacco

use across the nation and has supported funding and policies aimed at reducing the use of e-

cigarettes, especially amongst youth. She has continuously supported increases in the FDA’s

budget and its work towards reviewing and approving life-saving treatments and devices.

In the House, she sits on the House Cancer Caucus, the House Biomedical Research Caucus, and

the House NIH Caucus.

In 2019, Dr. Hendricks went above and beyond volunteering time to participate in ASCO's grassroots activities. From participating in ASCO's Advocacy at Home program, meeting with her elected officials in Pennsylvania and Maryland, or multiple trips to Capitol Hill, Dr. Hendricks was always happy to help educate lawmakers on ASCO’s legislative priorities.

Dr. Hendricks practices at Maryland Oncology Hematology in Bethesda, Maryland. Dr. Hendricks earned her medical degree from Johns Hopkins University School of Medicine, completed her residency at Johns Hopkins Hospital, and completed fellowship at Johns Hopkins University School of Medicine.

President’s CircleASCO advocates who regularly participate in more than one of ASCO's advocacy activities.

Eric Bernicker, MD

John Deeken, MD

Neelima Denduluri, MD, FASCO

Melissa Dillmon, MD, FASCO

Ralph Hauke, MD, FACP, FASCO

Marilyn Heine, MD

Randy Kimple, MD, PhD

Charles Miller, MD, FACP

ASCO 2019 Advocacy Champions

Advocate of the Year: Carolyn Hendricks, MD, FASCO

Kurt Oettel, MD, MBA, FACP

Ray Page, DO, PhD, FACOI, FASCO

Carole Seigel, MBA

Ashley Sumrall, MD, FACP

Joan Tashbar

Catherine Van Poznak, MD, FASCO

Jeffery Ward, MD, FASCO

Robin Zon, MD, FACP, FASCO

ASCO's Advocacy ActivitiesASCO provides volunteers with several opportunities to get involved in advocating on behalf of cancer care and our patients. These activities include: virtual advocacy (sending ACT Network emails); in person advocacy (conducting visits on Capitol Hill, with agency officials or at home in the congressional districts); engaging in grasstops advocacy (email/phone call with legislative staff, speaking on behalf of ASCO at briefings or providing hearing testimony, hosting lawmakers and staff for site visits at their practice locations). Listed below are the ASCO volunteers who are leaders in cancer care advocacy.

Speaker’s ClubASCO advocates who often participate in more than one of ASCO’s advocacy activities.

Peggy Bezruki, BC, RN

Howard Burris, MD, FACP, FASCO

John Cox, DO, FASCO, MBA, MACP

Laurie Gaspar, MD, MBA, FASTRO, FACR, FASCO

Thomas George, MD, FACP

Mark Henderson, MD

Tara Henderson, MD, MPH, FASCO

Sheetal Kircher, MD

Roger Klein, JD, MD

Shail Maingi, MD

Anthony Mega, MD

Senator’s ClubASCO advocates who participate in more than one of ASCO’s advocacy activities.

Holly Almond, NP, MSN, RN, BA

Samir Ambrale, MD, MPH

Muhammad Beg, MD, MS

Tithi Biswas, MD

Carlin Callaway, DNP, RN, AOCNP

Daniel Carrizosa, MD, MS

Robert Daly, MD, MBA

Sameer Desai, MD

Gail Eckhardt, MD, FASCO

Apar Ganti, MD

Arif Kamal, MD, MBA, MHS, FAAHPM, FASCO

Karen Knudsen, PhD, MBA

Inga Lennes, MD, MPH, MBA

Rami Manochakian, MD

ASCO 2019 Advocacy Champions

Sogol Mostoufi-Moab, MD, MSCE

Therese Mulvey, MD, FASCO

Martin Palmeri, MD, MBA

Gladys Rodriguez, MD

Trevor Royce, MD, MPH

Joel Saltzman, MD

Danielle Shafer, DO

Heloisa Soares, MD

Dorinda Sparacio, MS

Mylin Torres, MD

Jason Westin, MD, MS, FACP

Merry Markham, MD, FACP, FASCO

Heather McArthur, MD, MPH

Caroline Merritt, BA, MA

Joseph Muscato, MD

Zeina Nahleh, MD

Burton Needles, MD

Larissa Nekhlyudov, MD, MPH

Matthew Nwaneri, MD, MBA

Ann Partridge, MD, MPH, FASCO

Todd Pickard, PA-C, FASCO

Lori Pierce, MD, FASTRO, FASCO

Matt Sherer, MBA, MHA

Laura Tenner, MD, MPH

Alexandra Thomas, MD, FACP

Neeraj Agarwal, MD Cancer Communications Committee Holladay, UT @neerajaiims Charu Aggarwal, MD, MPH Leadership Development Program Penn Valley, PA

@CharuAggarwalMD Manmeet Singh Ahluwalia, MD, FACP Clinical Practice Guidelines Committee Westlake, OH @braintumordoc Imran Ali, MD, BA, MS ASCO Advocate Trumbull, CT Ajjai Shivaram Alva, MD Cancer Research Committee Ann Arbor, MI

Abeer Arain, MD, MPH

ASCO Advocate Houston, TX

Avan Armaghani, MD

ASCO Advocate Tampa, FL

@aarmaghanimd

Maria Quintos Baggstrom, FACP, MD

Cancer Education Committee Kirkwood, MO

@MariaBaggstrom Edward P. Balaban, DO, FACP, FASCO

Government Relations Committee Penllyn, PA

Lu Anne Bankert, CAE

State Affiliate Council Walkersville, MD

Eric Bernicker, MD

Cancer Prevention Committee Houston, TX @EricBernicker Monica M. Bertagnolli, MD, FACS, FASCO Chair of the ASCO Association Board Newton, MA Tithi Biswas, MD Cancer Research Committee Solon, OH A. William Blackstock, MD, FASCO ASCO Board of Directors Winston Salem, NC

Sibel Blau, MD

ASCO Association PAC Advisory Council

Seattle, WA

Arturo Loaiza-Bonilla, MD, MEd, FACP

ASCO Advocate Philadelphia, PA

@DrBonillaOnc Christopher Brett, MD Trainee & Early Career Council Nashville, TN @ChrisBrettMD Howard A. Burris, MD, FACP, FASCO ASCO & ASCO Association Board of Directors Nashville, TN

2020 Advocacy Summit Attendees

Leslie Byatt Cancer Research Committee Cedar Crest, NM Dana B. Cardin, MD, MSCI State Affiliate Council Nashville, TN @CardinMD Daniel R. Carrizosa, MD, MS Health Equity Committee Charlotte, NC @DCarrizosaMD Mercedes Castiel, MD Cancer Prevention Committee Pelham, NY Paul Celano, MD, FACP, FASCO State Affiliate Council Baltimore, MD @Pcelano Sunandana Chandra, MD Annual Meeting Faculty Chicago, IL Monica Sheila Chatwal, MD, BS Trainee & Early Career Council Tampa, FL Ronald Chen, MD, MPH, FASCO Cancer Survivorship Committee Overland Park, KS Anne C. Chiang, MD, PhD, FASCO Quality of Care Council Hamden, CT

@AnnechiangMD

Carol Christner, MA, CAE

ASCO Advocate Philadelphia, PA

Rise Marie Cleland Government Relations Committee Vancouver, WA Gary Irvin Cohen, MD, FASCO Measures Steering Group Palm Beach Gardens, FL John Vernon Cox, DO, FASCO, MBA, MACP Clinical Practice Committee Dallas, TX @jvcox Christopher D'Avella, MD ASCO Advocate Philadelphia, PA Jose R. Davila, MD State Affiliate Council Dorado, PR Zoneddy R. Dayao, MD Clinical Practice Guidelines Committee Albuquerque, NM Neelima Denduluri, MD, FASCO ASCO Association PAC Advisory Council Arlington, VA @ndenduluri1 Asha Dhanarajan, MD ASCO Advocate Chicago, IL Natalie R. Dickson, MD, MMHC, FACP Clinical Practice Committee Nashville, TN Melissa S. Dillmon, MD, FASCO Government Relations Committee Rome, GA

Chancellor Donald, MD State Affiliate Council New Orleans, LA Narjust Duma, MD Trainee & Early Career Council Madison, WI @NarjustDumaMD John Ellerton, MD Government Relations Committee Alumni Las Vegas, NV Lee M. Ellis, MD, FACS, FASCO ASCO Board of Directors Houston, TX @recnac1 Brie Fetherolf ASCO Advocate Boise, ID Douglas Flora, MD Board, Kentucky Society of Clinical Oncology Cincinnati, OH @DougFloraMD Gregg E. Franklin, MD, PhD Leadership Development Program Alumni Albuquerque, NM Laurie E. Gaspar, MD, MBA, FASTRO, FACR, FASCO ASCO & ASCO Association Board of Directors Denver, CO Thomas J. George, MD, FACP Continuing Education Committee Gainesville, FL @TGeorgeMD Thomas Giever, DO, MBA ASCO Advocate Muskego, WI

Jill Gilbert, MD, FACP, FASCO Government Relations Committee Nashville, TN Ashley Elizabeth Glode, BCOP, PharmD eLearning Editorial Board Aurora, CO Laura Goff, MD, MS Professional Development Committee Nashville, TN @drlauragoff Richard Goldberg, FACP, FASCO, MD ASCO Association PAC Advisory Council Morgantown, WV Jennifer J. Griggs, MD, MPH, FASCO Measures Task Force Ann Arbor, MI Michael L. Grossbard, MD Oncology Training Programs Committee New York, NY

R Donald Harvey, PharmD, BCOP, FCCP

Cancer Research Committee Avondale Estates, GA

@DrDonaldHarvey Ralph Hauke, FACP, FASCO, MD Government Relations Committee Omaha, NE @rhaukemd Daniel F. Hayes, MD, FACP, FASCO, BA Past ASCO President Ann Arbor, MI Arielle Heeke, MD ASCO Advocate Cramerton, NC

Marilyn Heine, MD, FACEP, FACP, FCPP Government Relations Committee Alumni Dresher, PA @marilynheinemd

Tara O. Henderson, MD, MPH, FASCO

ASCO Board of Directors Chicago, IL

@doctortara Carolyn Hendricks, MD, FASCO Government Relations Committee Chair Clearville, PA @carolyn5353 Paul Joseph Hesketh, MD, FASCO Clinical Practice Guidelines Committee Westwood, MA John M. Hill, Jr., MD ASCO Advocate Hanover, NH Leslie J. Hinyard, PhD, MSW Health Equity Committee Saint Louis, MO Clifford A. Hudis, MD, FACP, FASCO ASCO Chief Executive Officer New York, NY @CliffordHudis Sakeer Hussain, MD State Affiliate Council Omaha, NE Heather Marie Hylton, PA-C, FASCO JCO Oncology Practice Editorial Board New York, NY @hmhyltonpac Blair Billings Irwin, MD President-Elect, Washington State Medical Oncology Society Gig Harbor, WA

Mohammad Jahanzeb, MD, FACP, FASCO Quality of Care Council Boca Raton, FL Sanford Earl Jeames, PhD Health Equity Committee Austin, TX @JeamesSailor

Bruce E. Johnson, MD, FASCO

Past ASCO President Brookline, MA

Lee Jones, MBA

ASCO Advocate Arlington, VA

@LeeJonesMBA Arif Kamal, MD, MBA, MHS, FAAHPM, FASCO Quality of Care Council Chapel Hill, NC @arifkamalmd Jasmine Kamboj, MD, MBBS

Health Equity Committee Woodbury, MN Charles Stewart Kamen, PhD, MPH Health Equity Committee Rochester, NY Sharad Khurana, MD, MSc Trainee & Early Career Council Tucson, AZ Randall J. Kimple, MD, PhD Cancer Communications Committee Madison, WI @kimplerandall Roger David Klein, MD, JD Government Relations Committee Alumni Beachwood, OH @RogerDKlein

Mary M. Klix, MD ASCO Advocate Eagle River, AK Miriam Knoll, MD Cancer Communications Committee Woodmere, NY @MKnoll_MD Michael P. Kosty, MD, FACP, FASCO ASCO & ASCO Association Board of Directors Carlsbad, CA

Angela Ladner Executive Director, Mississippi Oncology Society Jackson, MS @MissOncoSociety Thomas William LeBlanc, MD, MA, MHS, FAAHPM Publishing Research Group Hillsborough, NC

@tomleblancMD

Steve Lee, MD

ASCO AMA Delegation Oakland, CA @steveleeyc Inga Tolin Lennes, MD, MPH, MBA ASCO Advocate Auburndale, MA @ilennes Mark Andrew Lewis, MD Cancer Prevention, Risk Reduction, and Genetics Sandy, UT @marklewismd Stephen Liu, MD ASCO Advocate Bethesda, MD @StephenVLiu

Noelle LoConte, MD CancerLinQ Oncology Informatics Task Force Madison, WI @loconte Gilberto Lopes, MD, MBA, FASCO Social Media Working Group Miami, FL @glopesMD Ana Maria Lopez, MD, MPH Cancer Prevention Committee Philadelphia, PA @anamarialopezmd Emil Lou, MD, PhD Social Media Working Group Minneapolis, MN @cancerassassin1

Allison Magnuson, DO

Cancer Research Committee Pittsford, NY

@DrAllisonMags Joshua Mammen, MD ASCO Advocate Leawood, KS @joshuamammen Ana Velazquez Mañana, MD, MS Trainee & Early Career Council San Francisco, CA @anavmanana Rami Manochakian, MD ASCO Advocate Jacksonville, FL Joshua Mansour, MD ASCO Advocate Duarte, CA

Thomas A. Marsland, MD, FASCO ASCO Association PAC Advisory Council Chair Fleming Island, FL Gregory Masters, MD, FACP, FASCO Cancer Prevention Committee Kennett Square, PA @DrGregMasters Julia Maues ASCO Advocate Washington, DC @itsnot_pink Barbara L. McAneny, MD, MACP, FASCO ASCO AMA Delegation Albuquerque, NM @BarbaraMcAneny Bradley McGregor, MD Leadership Development Program Alumni Needham, MA @Bradmcg04

Anthony Mega, MD

ASCO Advocate South Kingstown, RI Jane Lowe Meisel, MD Cancer Communications Committee Atlanta, GA @jane_meisel Neal Meropol, MD, FASCO Cancer Research Committee Brooklyn, NY @nealmeropol Caroline Merritt, BA, MA State Affiliate Council Meridian, ID Charles F. Miller, MD, FACP State Affiliate Council East Honolulu, HI

Alicia Morgans, MD, MPH

JCO Editorial Board Chicago, IL

@capsurvivorship Beverly Moy, FASCO, MD, MPH Government Relations Committee Alumni Needham, MA @BeverlyMoy Therese Marie Mulvey, MD, FASCO Quality of Care Council Charlestown, MA @mulvt3 Burton M. Needles, MD TAPUR Molecular Tumor Board St. Louis, MO Larissa Nekhlyudov, MD, MPH Survivorship Guideline Advisory Group Newton Highlands, MA @DrN_CancerPCP Craig R. Nichols, MD, FACP, FASCO CancerLinQ Board of Governors Beaverton, OR @testiscancer Kristina Novick, MD ASCO AMA Delegation Rose Valley, PA Kurt R. Oettel, FACP, MBA, MD Government Relations Committee LaCrosse, WI @KurtOettelMD David Oubre, MD CancerLinQ Physician Advisory Committee Mandeville, LA

Ray D. Page, DO, PhD, FACOI, FASCO State Affiliate Council Aledo, TX @raypagedophd

Martin Palmeri, MD, MBA

Government Relations Committee Asheville, NC

@Doctor_Palmeri Minggui Pan, MD, PhD ASCO Advocate Saratoga, CA Aparna Raj Parikh, MD Taxonomy Committee Newton, MA @aparna1024 Timil Patel, MD ASCO Advocate New Haven, CT @timilhpatel

Brian Edward Persing, MD

State Affiliate Council Ocean Springs, MS

Dorothy Phillips

ASCO Advocate Riverview, FL

Todd Alan Pickard, PA-C, FASCO

Clinical Practice Committee Houston, TX

Lori J. Pierce, MD, FASTRO, FASCO

ASCO President Ann Arbor, MI Luis E. Raez, MD, FACP, FCCP State Affiliate Council Doral, FL @LuisERaez1

Marissa Rivera, MBA ASCO Advocate Medford, OR @marissamriv Gladys Isabel Rodriguez, MD Government Relations Committee San Antonio, TX @RodriguezGIMD Trevor Royce, MD, MPH Clinical Practice Committee Chapel Hill, NC @tjroycemd

Joel Saltzman, MD

Clinical Practice Committee Beachwood, OH

Michael A. Savin, MD

Cancer Education Committee Tigard, OR

Kala Seetharaman, MD

State Affiliate Council Ashland, MA

Carole Seigel, MBA

ASCO Advocate Brookline, MA

Aditi Shastri, MD

Improving Clinical Trials Participation Among Diverse Populations Task Force Astoria, NY

@aditishasMD Eugene Shenderov, MD, PhD Government Relations Committee Baltimore, MD @DocEShenderov

Gregg Shepard, MD

State Affiliate Council Nashville, TN

Samuel Silver, MD, PhD, MACP, FRCP, FASCO

Clinical Practice Committee Ann Arbor, MI

Miranda Sloan ASCO Advocate LaGrange, KY

@kyscocancer Heloisa P. Soares, MD Technology Research Group Holladay, UT @helops79 Piyush Srivastava, MD Government Relations Committee Moraga , CA John H. Stewart, MD ASCO Advocate Clemmons, NC Ishwaria Mohan Subbiah, MD, MS Social Media Working Group Houston, TX @ishwariaMD Latha Subramanian, MBChB State Affiliate Council Anchorage, AK Preeti Sudheendra, MD Measures Task Force Moorestown, NJ @DrPKSudi

Ashley Love Sumrall, MD, FACP

Clinical Practice Committee Charlotte, NC

@ashleysumrallmd Banu Symington, MD, MACP Ethics Committee Rock Springs, WY Winston Tan, MD, MS Oncology Training Programs Committee Jacksonville, FL Laura Tenner, MD, MPH Government Relations Committee San Antonio, TX Alexandra Thomas, MD, FACP Government Relations Committee Lewisville, NC Christian A. Thomas, MD Clinical Practice Committee Scarborough, ME Apostolia M. Tsimberidou, MD, PhD Leadership Development Program Alumni Houston, TX Catherine Van Poznak, MD, FASCO Leadership Development Program Alumni Dexter, MI Vamsidhar Velcheti, MD, FACP, FCCP Leadership Development Program Scarsdale, NY @vamsivelcheti Alan Venook, MD, FASCO Government Relations Committee Alumni Millbrae, CA

Vyshak Alva Venur, MD Professional Development Committee Seattle, WA @VenurVyshak Gina M. Villani, MD, MPH Cancer Prevention, Risk Reduction, and Genetics Bayside, NY Everett Vokes, MD, FASCO ASCO President-Elect Chicago, IL Julie Vose, MD, MBA, FASCO Government Relations Committee Omaha, NE @drjulievose Mark Walshauser, MD Clinical Practice Committee Ladue, MO @walshauserMD Jeffery C. Ward, MD, FASCO Government Relations Committee Alumni Shoreline, WA Susan Weiner, PhD ASCO Advocate Brooklyn, NY Tracey Weisberg, MD, FASCO ASCO Board of Directors Falmouth, ME Jason Westin, MD, MS, FACP Government Relations Committee Houston, TX @DrJasonWestin Karen Winkfield, MD, PhD Government Relations Committee Winston Salem, NC @DrWinkfield

Marie Wood, MD, FASCO State Affiliate Council Burlington, VT Joanna C. Yang, MD, MPH ASCO Advocate St Louis, MO Yousef Zakharia, MD ASCO Advocate North Liberty, IA Robin Zon, MD, FACP, FASCO ASCO Association PAC Advisory Council Niles, MI

How to Access Your Congressional Meetings Schedule

ASCO hopes to ensure your virtual congressional meetings are glitch-free. Personalized schedules will be

available through an online portal this year. Please keep in mind that meetings shift, so it is important to

refer to this site periodically leading up to September 16th and that morning. If urgent changes or

cancellations occur the day of, the portal will update but we will also contact you directly. Staff will be

available to troubleshoot unforeseen technical issues. Please save these instructions for reference on

September 16th. If you have any issues accessing your schedule, please contact

AdvocacySummit@asco.org.

How to Log In:

• Click here or go to http://clients.primeadvocacy.com/attendee/login

• Login with the email address you used to register for the Advocacy Summit

What You Will See:

• Meeting Status – the status of each meeting is displayed in the upper right-hand corner. Statuses include confirmed, in progress, and no response. Please keep in mind these meetings are fluid and are subject to change. You will only be participating in confirmed meetings.

• Time – this is the start time of your meeting. All times are displayed in Eastern Time. Please dial

into your call 5 minutes prior to the start time to plan with your group regarding who will open

the meeting and who will highlight each issue.

• Office of – the name of the Member of Congress. This will be listed for every meeting, but you may be meeting with staff rather than the Member.

• Meeting with – the name of the staffer with whom you will be meeting. The name of the Member of Congress will also be listed in this field if he or she is expected to join.

• Location - the conference call phone number and access code are listed in this field. You and

your meeting group will have one phone number and access code throughout the day, unless the

Congressional office prefers to use their conference lines, in which case the numbers will be

different. If your meeting is a video conference, the Zoom link will be shown in this field. Please

download the Zoom application prior to September 16 by clicking here and ensure your camera

is on.

• Team Lead – if a member has been designated to open a meeting, they will be noted here. In

meetings where just one participant is a constituent, it is appropriate for the constituent to open

the meeting. If no team lead is designated, please assign among yourselves one of the

constituents in the group to take the lead.

• Special Notes – if the Member of Congress is a cosponsor of a key bill, on a key Committee, or

has signed on to a Dear Colleague letter in support of our issues, that will be noted here.

• Talking Points – a link to the key messages document will be accessible via link, along with the

suggested script and the “help” phone number for scheduling issues. A second phone number is

listed if you any questions regarding the legislative messaging, or you can email

AdvocacySummit@asco.org with questions.

• Additional Attendees – attendees in each of your meetings are noted here.

• Meeting Notes – please provide important feedback on your lawmaker’s response to each issue

discussed and indicate if the Member or their staff has asked for materials to be sent to them

here. This information is crucial for ASCO staff to follow-up with congressional offices.

Important Scheduling Note:

• Your schedule may change. Please login periodically to check for any updates. If you provided a cell number when you registered for the Summit, any last minute changes made to your schedule on the day of September 16 will be sent to you directly via text message – those changes also will be reflected in your online schedule. If you did not provide a cell phone number, we will contact you with those changes over email.

In events where you can speak directly to the presenters (also hosted by

WebEx), if you wish to speak, please unmute yourself by clicking on the

microphone in WebEx toolbar, as seen to the right. As a reminder, please keep

your microphone muted if you are note speaking.

WebEx How-to: Dialing in to Virtual Events

The Virtual Advocacy Summit training webinars and keynote speaker will be hosted through ASCO’s WebEx Event Center. For each event, you will join as an attendee. Please note that you will be muted upon logging in to each event. Some of these events will be “listen only,” while in other events you will be able to speak directly with the presenter to ask questions. We will note at the beginning of each event if it is a “listen only,” or if you will be able to unmute yourself to speak with the presenters. Important Note: We will not use WebEx for the Congressional meetings on the 16th. The dial-in number or Zoom link for each meeting will be in your Congressional meetings schedule online. Log-in Instructions: Please log-in to the WebEx using the link that is provided in the event email or in your calendar invite sent by ASCO staff. You will then enter your name and email address. If a password is required, please enter the password ASCO (case sensitive). Clicking the provided link will allow you to see the slides or panelists for each virtual event. You will then be asked to select your audio connection, please choose the “Call Me” function seen below:

Please click here to test your ability to connect to WebEx prior to the first webinar. For further information on how to log-in to a WebEx meeting, please watch this instructional video.

Enter your phone number in the correct field, and Webex will call you – all you need to do is answer and you’re in the event. If you run into issues with the “call me” function, please choose the dial in function, and enter the dial-in information included in the meeting information. You can also join by computer audio if necessary. In listen only events you will be muted upon entry

and unable to speak directly to the presenter and

we ask that you submit your questions via the chat

function located in the lower right hand corner

(please see the screenshot to the left for an

example). Please be sure to send your chat to “All

Panelists”. A moderator will read your question to

the panelists.